Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report

Fig. 2

CT of the abdomen showing the segment 3 liver lesions at baseline (Panel A 20180207), 4 months (Panel A 20180612), 6 months (Panel A 20180822) and 9 months (Panel A 20181112) after treatment with Pembrolizumab and Lenvatinib, respectively. Graphical depiction of change in the ɑ-fetoprotein over time (Panel B). Graphical depiction of change in HBV-DNA over time (Panel C)

Back to article page
\